Infectious Disease reimbursement alerts

Baxter Healthcare's new dosage form of cefepime (injectable, NDA050817) follows the Part B billing pathway, consistent with its intravenous/injection route of administration typically administered in

Zevtera (ceftobiprole medocaril sodium) is an intravenous antibiotic approved via NDA218275, administered as a reconstituted powder for IV infusion, placing it squarely in the Medicare Part B billing

REXTOVY (naloxone hydrochloride), a nasal spray, will likely fall under Medicare Part D for oral drugs, as it is not injectable and thus not eligible for Part B billing. Billing teams should consider

Linezolid for suspension is an oral medication that will be billed under Medicare Part D. Since it does not have an injectable form, there will be no assignment of J-codes. Billing teams should monito

ZYVOX (Linezolid) is an injectable drug likely to receive a J-code assignment for billing. It will be billed under Part B, and potential ASP+6% payment may apply due to its injectable nature.

ZYVOX (Linezolid) is an oral antibacterial drug that falls under Medicare Part D for billing. Since it is not an injectable, a J-code assignment is not applicable. No pass-through payment or ASP+6% wi

The new formulation of Linezolid, administered intravenously, is likely to be assigned a J-code for Medicare billing. As an injectable Part B drug, it may also qualify for pass-through payment and wil

With the approval of Vancomycin Hydrochloride as an injectable solution, it is likely to be assigned a J-code for Medicare billing. The reimbursement may follow the ASP+6% model due to its injectable

As a newly approved oral drug, Malarone will be billed under Medicare Part D. Since it is a combination therapy for malaria, billing teams should note potential variations in coverage and reimbursemen

The new LCD for Molecular Syndromic Panels will streamline the billing process for pathogen identification testing by establishing clear guidelines. This could potentially supports compliance with updated rates for facilit

The Noridian LCD for Blood Product Molecular Antigen Typing effective from January 22, 2026, could substantially impact reimbursement for labs specializing in this testing. Labs should prepare for upd

The effective date of the new MolDX guidelines for Blood Product Molecular Antigen Typing will shift billing requirements, potentially impacting reimbursement for impacted services. Providers should p

The implementation of this LCD on molecular syndromic panels will significantly influence billing practices for infectious disease testing. Providers will need to ensure they comply with the outlined

The new LCD regarding MolDX: Molecular Syndromic Panels for Infectious Disease may impact billing practices significantly for laboratories involved in pathogen identification testing. Providers should

The new LCD for Multiplex Gastrointestinal Pathogen Panel tests addresses billing guidelines for acute gastroenteritis. It is crucial for providers to understand the changes in coverage and documentat

The new MolDX for Blood Product Molecular Antigen Typing will likely lead to changes in billing protocols, impacting how blood products are reimbursed under Medicare. Providers must familiarize themse

The implementation of MolDX for molecular syndromic panels may significantly enhance pathogen identification capabilities for infectious diseases. This change will likely impact claims processing and